Dupixent® (dupilumab) recommended for eu approval by the chmp for the treatment of prurigo nodularis

Recommendation is based on data from two pivotal trials showing dupixent significantly improved itch, skin lesions and health-related quality of life in adults with prurigo nodularis if approved, dupixent would be the first and only targeted medicine specifically indicated for prurigo nodularis in the european union tarrytown, n.y. and paris , nov. 11, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the european medicines agency's committee for medicinal products for human use (chmp) has adopted a positive opinion, recommending the approval of dupixent® (dupilumab) in the european union (eu) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
REGN Ratings Summary
REGN Quant Ranking